ViaDerma Announces Posting of Annual Report and Ongoing Evaluation of Public Status in Response to Market Changes
ViaDerma (OTC Expert Market: VDRM), a specialty pharmaceutical company, has announced the posting of its 2024 Annual Report on its company website due to restrictions on posting directly to OTC Markets as a result of its Expert Market designation.
The company is actively evaluating strategic options regarding its public status in response to changes in OTC Markets and the introduction of the OTCID exchange. CEO Dr. Christopher Otiko emphasized the company's commitment to transparency and shareholder value while maintaining operational focus.
ViaDerma (OTC Expert Market: VDRM), un'azienda farmaceutica specializzata, ha annunciato la pubblicazione del suo Rapporto Annuale 2024 sul sito web aziendale a causa delle restrizioni che impediscono la pubblicazione diretta su OTC Markets, dovute alla sua designazione Expert Market.
L'azienda sta valutando attivamente opzioni strategiche riguardo al suo status pubblico in risposta ai cambiamenti di OTC Markets e all'introduzione della borsa OTCID. Il CEO, Dr. Christopher Otiko, ha sottolineato l'impegno dell'azienda verso la trasparenza e il valore per gli azionisti, mantenendo al contempo il focus operativo.
ViaDerma (OTC Expert Market: VDRM), una empresa farmacéutica especializada, ha anunciado la publicación de su Informe Anual 2024 en su sitio web corporativo debido a las restricciones para publicar directamente en OTC Markets como resultado de su designación Expert Market.
La empresa está evaluando activamente opciones estratégicas respecto a su estatus público en respuesta a los cambios en OTC Markets y la introducción del intercambio OTCID. El CEO, Dr. Christopher Otiko, enfatizó el compromiso de la empresa con la transparencia y el valor para los accionistas, manteniendo el enfoque operativo.
ViaDerma (OTC Expert Market: VDRM)는 전문 제약 회사로서, Expert Market 지정으로 인해 OTC Markets에 직접 게시할 수 없는 제한 때문에 회사 웹사이트에 2024 연례 보고서를 게시했다고 발표했습니다.
회사는 OTC Markets의 변화와 OTCID 거래소 도입에 대응하여 상장 상태에 대한 전략적 옵션을 적극적으로 검토하고 있습니다. CEO인 Dr. Christopher Otiko는 운영에 집중하면서 투명성과 주주 가치를 유지하겠다는 회사의 의지를 강조했습니다.
ViaDerma (OTC Expert Market : VDRM), une société pharmaceutique spécialisée, a annoncé la publication de son Rapport Annuel 2024 sur son site internet en raison des restrictions empêchant la publication directe sur OTC Markets liées à sa désignation Expert Market.
L'entreprise évalue activement des options stratégiques concernant son statut public en réponse aux changements d'OTC Markets et à l'introduction de la bourse OTCID. Le PDG, Dr Christopher Otiko, a souligné l'engagement de la société envers la transparence et la création de valeur pour les actionnaires tout en maintenant son focus opérationnel.
ViaDerma (OTC Expert Market: VDRM), ein spezialisiertes Pharmaunternehmen, hat die Veröffentlichung seines Jahresberichts 2024 auf seiner Unternehmenswebsite bekannt gegeben, da aufgrund der Expert Market-Einstufung Einschränkungen für eine direkte Veröffentlichung bei OTC Markets bestehen.
Das Unternehmen prüft aktiv strategische Optionen hinsichtlich seines öffentlichen Status als Reaktion auf Änderungen bei OTC Markets und die Einführung der OTCID-Börse. CEO Dr. Christopher Otiko betonte das Engagement des Unternehmens für Transparenz und Aktionärswert bei gleichzeitiger operativer Fokussierung.
- Company maintains transparency by making Annual Report publicly accessible
- Management actively evaluating strategic options for public status
- Current Expert Market designation restricts financial reporting on OTC Markets platform
- Potential regulatory and compliance challenges due to OTC Markets structural changes
LOS ANGELES, July 16, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, announced today that its 2024 Annual Report has been posted to the company’s official website, www.viaderma.com.
Due to the company’s current designation on the OTC Markets Expert Market, financial reports are not permitted to be posted directly to the OTC Markets platform. As part of its ongoing commitment to transparency, ViaDerma is making the Annual Report publicly accessible through its website.
The company also noted it is actively evaluating all strategic options related to its public status, including possible responses to recent structural changes across the OTC Markets and the introduction of the new OTCID exchange. While no decisions have been made, ViaDerma is carefully assessing what will best support its long-term growth and shareholder interests.
“We remain fully operational and committed to transparency, accountability, and maximizing value for our shareholders,” said Dr. Christopher Otiko, CEO of ViaDerma. “As the regulatory landscape continues to evolve, we are taking measured steps to ensure ViaDerma remains well-positioned, compliant, and focused on executing our core business objectives.”
About ViaDerma, Inc.
ViaDerma, Inc. is a specialty pharmaceutical company committed to bringing new products to market and licensing its innovative transdermal delivery technology to other companies in the pharmaceutical space. Its lead product, Vitastem Ultra, is a powerful topical antibiotic formulated to treat a variety of chronic and acute skin infections.
Forward-Looking Statement Disclaimer:
This press release may contain forward-looking statements, including those relating to the Company’s evaluation of strategic options. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that may cause actual results to differ materially. No assurance can be given that any specific action will be taken. The Company expressly disclaims any intention or obligation to update any forward-looking statement if circumstances change.
For more information, please visit: www.viaderma.com
Contact information:
Investor Relations
Email: ir@viaderma.com
Phone: 310-734-6111
FAQ
What did ViaDerma (VDRM) announce about its 2024 Annual Report?
Why can't ViaDerma post its financial reports on OTC Markets?
What strategic options is ViaDerma (VDRM) considering in 2025?
Who is the current CEO of ViaDerma?
What is ViaDerma's commitment to shareholders according to the announcement?
